Completed Infection & Immunity Cancer

saRNA COVID-19 Vaccine Clinical Trial

Funder NIHR (part of DHSC)
Recipient organisation Imperial College London Source-published name: Imperial College of Science, Technology and Medicine
Funding £3.2M
Period May 2020 — Oct 2022

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

View the original record at the funder ↗

Related Research

Grants with similar aims, by meaning.

A first-in-human clinical trial to assess the safety and immunogenicity of a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19
CRF462- A trial to evaluate SARS-CoV-2 recombitant nanoparticle vaccine
Unravelling the impact of RNA vaccine induced inflammation on adaptive immunity.
COVID-19 Clinical Neuroscience Study COVID-19 Clinical Neuroscience Study (COVID-CNS), part of the COVID-19 Research Cohort of the NIHR Bioresource Research Tissue Bank
An adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus.

Original classification

Research

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.